Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grifols ADR Representing One Non-Voting Ord Shs Class B GRFS

Healthcare Biotechnology
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale... see more

Recent & Breaking News (NDAQ:GRFS)

Grifols agrees to acquire Hologic's share of NAT donor screening unit for USD 1,850 million

PR Newswire December 14, 2016

Hologic to Divest Blood Screening Business to Partner Grifols for $1.85 Billion

PR Newswire December 14, 2016

Research Reports Coverage on Biotech Stocks -- Biogen, BioMarin Pharma, Seattle Genetics, and Grifols

PR Newswire November 30, 2016

The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests

Business Wire October 20, 2016

Research Reports Initiation on Biotech Stocks -- Heat Biologics, Geron, Seattle Genetics, and Grifols

PR Newswire October 19, 2016

Grifols Opens Diagnostic Training Center in Dubai

PR Newswire Europe Non Regulatory September 4, 2016

Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century

PR Newswire August 22, 2016

FDA Approves Use Of Zika Virus Blood Screener From Hologic And Grifols

Benzinga.com  June 20, 2016

Hologic And Grifols Get FDA Approval For Procleix Zika Virus Assay

Benzinga.com  June 20, 2016

FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Grifols to Screen the U.S. Blood Supply Under an IND Study Protocol

PR Newswire June 20, 2016

Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology

PR Newswire June 8, 2016

Singulex announces a $50 million investment by Grifols for a 20% stake in the company

PR Newswire May 31, 2016

Grifols 2015 Annual Report on Form 20-F filed with the SEC on April 5, 2016

PR Newswire April 5, 2016

How it All Plays Out - Analyst Reports on KapStone Paper and Packaging, Heartland Express, Grifols and Knoll

Accesswire January 13, 2016

Grifols 2014 Annual Report on Form 20-F filed with the SEC on April 1, 2015

PR Newswire April 1, 2015

Grifols to make a major equity investment in Alkahest

PR Newswire March 4, 2015

Grifols opens state-of-the-art facility in Clayton, NC to help advance treatment of rare and life-threatening diseases

PR Newswire June 17, 2014

Talyst Announces GRIFOLS Reseller Agreement

PR Newswire December 9, 2013

Aradigm Announces Changes to Its Board of Directors

Business Wire September 18, 2013

Grifols Announces Winners of the 10th Annual eALTA Research Fellowship at 2013 ERS Congress

PR Newswire September 9, 2013